• Publications
  • Influence
Biology and therapeutic advances for pediatric osteosarcoma.
Osteosarcoma is the most common malignant bone tumor in children and adolescents. Survival for these patients was poor with the use of surgery and/or radiotherapy. The introduction of multi-agentExpand
  • 585
  • 37
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis
Metastatic cancers, once established, are the primary cause of mortality associated with cancer. Previously, we used a genomic approach to identify metastasis-associated genes in cancer. From thisExpand
  • 652
  • 31
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success.
Osteosarcoma is the bone tumor that most commonly affects children, adolescents, and young adults. Before 1970, treatment primarily included surgical resection. However, the introduction ofExpand
  • 514
  • 14
  • PDF
Osteosarcoma: a review of diagnosis, management, and treatment strategies.
Despite significant advancements in the diagnosis and treatment of osteosarcoma to date, overall survival has remained relatively constant for over 2 decades. The challenge in osteosarcoma stems fromExpand
  • 356
  • 14
Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma.
There are two telomere maintenance mechanisms (TMMs) in human tumors, telomerase activation (TA) and, more rarely, the process termed alternative lengthening of telomeres (ALT). Unlike mostExpand
  • 171
  • 12
  • PDF
Expression of HER2/erbB-2 correlates with survival in osteosarcoma.
PURPOSE In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified. The aim of this study was to determine whether human epidermal growth factorExpand
  • 296
  • 11
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse.
PURPOSE EWS-FLI1 fusion type, p53 mutation, and homozygous deletion of p16/p14ARF have each been shown to be prognostically significant in Ewing sarcoma (ES). We provide the first combined prognosticExpand
  • 224
  • 10
Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary.
  • R. Gorlick, Peter Anderson, +36 authors B. Anderson
  • Medicine
  • Clinical cancer research : an official journal of…
  • 15 November 2003
Childhood osteogenic sarcoma (OS) is a rare bone cancer occurring primarily in adolescents. The North American pediatric cooperative groups have performed a series of clinical treatment trials inExpand
  • 166
  • 10
  • PDF
Intrinsic and acquired resistance to methotrexate in acute leukemia.
Methotrexate, a folic acid antagonist, is used extensively not only for the treatment of cancer but also for the treatment of rheumatoid arthritis, psoriasis, and autoimmune disease and for theExpand
  • 247
  • 9
Chemotherapy resistance in osteosarcoma: current challenges and future directions
For patients with osteosarcoma, the use of chemotherapy has improved survival from 11% with surgical resection alone in the 1960s, to 70% by the mid-1980s. However, survival has since plateaued,Expand
  • 290
  • 8